Diazepam (Valtoco) vs Midazolam (Nayzilam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Valtoco)
Marketed by Neurelis, Inc.
NCT02721069 · Phase 3 · completed
The study was open-label, nonrandomized, and had no placebo or active comparator, so it provides uncontrolled safety and treatment-exposure information rather than comparative evidence of effectiveness. Its primary endpoint was the number of participants receiving NRL-1 over 12 months, not a hard clinical seizure outcome, and no formal primary-endpoint comparison was applicable.
Next expected readout: December 2026 · NCT06346262 (registry estimate)
Reported efficacy
Number of Participants Who Received NRL-1 (Valtoco) (12 months): Number of Participants Who Received NRL-1 (Valtoco) (12 months): NRL-1 5mg 9 Participants | NRL-1 10mg 54 Participants | NRL-1 15 mg 46 Participants | NRL-1 20mg 54 Participants (not_applicable)
Result source: NCT02721069
Midazolam (Nayzilam)
Marketed by UCB
NCT01390220 · Phase 3 · terminated
This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).
Reported efficacy
Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 (met)
Result source: NCT01390220
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Diazepam (Valtoco) | Midazolam (Nayzilam) |
|---|---|---|
| Seizure frequency, % change | —Not reported | —Not reported |
| 50% responder rate | —Not reported | —Not reported |
| Seizure freedom | —Not reported | 54.8% vs 38.7%+16.1 vs placeboNCT01999777 |
Seizure frequency, % change
- Diazepam (Valtoco)
- —Not reported
- Midazolam (Nayzilam)
- —Not reported
50% responder rate
- Diazepam (Valtoco)
- —Not reported
- Midazolam (Nayzilam)
- —Not reported
Seizure freedom
- Diazepam (Valtoco)
- —Not reported
- Midazolam (Nayzilam)
- 54.8% vs 38.7%+16.1 vs placeboNCT01999777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Diazepam (Valtoco): 3 of 4 rows · Midazolam (Nayzilam): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Diazepam (Valtoco) | Midazolam (Nayzilam) |
|---|---|---|
| Dropout rate | —20mga NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 show 4 more results—15mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 —10mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 —5mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 5.3% NCT02724423 · Phase 1 · registry result, not featured evidence | —5 mg + 5 mga NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 31.2%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Discontinued due to AEs | —20mga NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 show 4 more results—15mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 —10mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 —5mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 — NCT02724423 · Phase 1 · registry result, not featured evidence | —5 mg + 5 mga NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 5.8%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 — NCT01999777 · Phase 3 · monotherapy |
| Serious AEs | 24.1%20mga NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 show 4 more results32.6%15mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 37%10mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 22.2%5mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 1.8% NCT02724423 · Phase 1 · registry result, not featured evidence | 0%5 mg + 5 mga NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results0%5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 0.7%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Most frequent reported AEs | 20mga nasal discomfort 11.1% nasopharyngitis 7.4% upper respiratory tract infection 7.4% NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 show 4 more results15mg seizure 15.2% upper respiratory tract infection 15.2% nasal discomfort 8.7% NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 10mg nasopharyngitis 22.2% pyrexia 18.5% upper respiratory tract infection 16.7% NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 5mg influenza 33.3% diarrhoea 22.2% nasopharyngitis 11.1% NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 dysgeusia 5.3% nasal discomfort 3.5% nasopharyngitis 3.5% NCT02724423 · Phase 1 · registry result, not featured evidence | 5 mg + 5 mga nasal discomfort 16.3% (placebo 7.3%) somnolence 9.3% (placebo 9.8%) throat irritation 7% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 show 3 more results5 mg only somnolence 9.9% (placebo 9.8%) headache 6.6% (placebo 0%) nasal discomfort 5.5% (placebo 7.3%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 7.3%) somnolence 9.6% (placebo 9.8%) lacrimation increased 6.8% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 16.1%) nausea 9.7% (placebo 3.2%) throat irritation 9.7% (placebo 9.7%) NCT01999777 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Midazolam (Nayzilam)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Valtoco)'s landscape · Midazolam (Nayzilam)'s landscape